TFC Financial Management Inc. Has $7.43 Million Position in Johnson & Johnson (NYSE:JNJ)

TFC Financial Management Inc. cut its position in Johnson & Johnson (NYSE:JNJ) by 0.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,398 shares of the company’s stock after selling 122 shares during the quarter. Johnson & Johnson comprises about 1.2% of TFC Financial Management Inc.’s holdings, making the stock its 10th largest position. TFC Financial Management Inc.’s holdings in Johnson & Johnson were worth $7,433,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in JNJ. Stanley Laman Group Ltd. lifted its stake in shares of Johnson & Johnson by 38.9% during the 4th quarter. Stanley Laman Group Ltd. now owns 2,407 shares of the company’s stock valued at $348,000 after buying an additional 674 shares in the last quarter. Park Capital Management LLC WI bought a new stake in Johnson & Johnson during the 4th quarter valued at $902,000. Consolidated Planning Corp lifted its position in shares of Johnson & Johnson by 59.0% during the fourth quarter. Consolidated Planning Corp now owns 9,690 shares of the company’s stock worth $1,401,000 after acquiring an additional 3,594 shares in the last quarter. Three Bridge Wealth Advisors LLC boosted its holdings in shares of Johnson & Johnson by 4.7% in the fourth quarter. Three Bridge Wealth Advisors LLC now owns 8,011 shares of the company’s stock worth $1,159,000 after acquiring an additional 359 shares during the period. Finally, Naples Global Advisors LLC raised its stake in shares of Johnson & Johnson by 1.2% during the 4th quarter. Naples Global Advisors LLC now owns 46,070 shares of the company’s stock valued at $6,663,000 after purchasing an additional 539 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.7 %

Shares of NYSE:JNJ opened at $156.20 on Friday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The stock’s 50-day moving average price is $147.87 and its 200-day moving average price is $156.00. The stock has a market capitalization of $376.08 billion, a P/E ratio of 23.49, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same period in the previous year, the firm earned $2.29 EPS. The business’s quarterly revenue was up 5.3% on a year-over-year basis. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.18%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Insider Activity

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ? increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the subject of several analyst reports. Wolfe Research assumed coverage on Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Guggenheim boosted their price objective on shares of Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Citigroup lowered their target price on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Finally, Leerink Partners dropped their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $170.67.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.